BioSig Technologies Inc (NASDAQ:BSGM) CEO Kenneth Londoner tells Proactive the group's subsidiary ViralClear Pharmaceuticals, Inc is teaming up with Sorrento Therapeutics, Inc. (NASDAQ: SRNE) to advance the fight against the coronavirus. Londoner says the two biotechs will look at the effective doses between the two drugs already in human clinical trials and will try to specifically demonstrate that the combined benefits in strengthening and accelerating viral clearance exceed what each drug could deliver by itself.
BioSig teams up with Sorrento Therapeutics to fight the coronavirus with a combination treatment
Quick facts: BioSig Technologies, Inc.
Price: 4.82 USD
Market Cap: $148.07 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of BioSig Technologies, Inc. named herein, including the promotion by the Company of BioSig Technologies, Inc. in any Content on the Site, the...FOR OUR FULL DISCLAIMER CLICK HERE